Arcturus Therapeutics Holdings Inc. Income Statement
ARCT|7 years of annual SEC 10-K data (FY2019-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 7 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Revenue
$82M
FY2025
Gross Profit
N/A
FY2025
Operating Income
-$76M
FY2025
Net Income
-$66M
FY2025
Arcturus Therapeutics Holdings Inc. reported $82M in revenue and $66M in net loss for FY2025. Revenue has grown at a 31.7% compound annual rate over the past 6 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 1/9 criteria passed
- Currently unprofitable: Net income is negative
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $82.0M | $152.3M | $166.8M | $12.4M | $12.4M | $15.8M | $15.8M |
| SG&A Expense | $46.1M | $52.8M | $52.9M | $41.5M | $41.5M | $20.6M | $20.6M |
| R&D Expense | $112.2M | $195.2M | $192.1M | $173.8M | $173.8M | $17.0M | $17.0M |
| Operating Income | -$76.3M | -$95.7M | -$78.2M | -$202.9M | -$202.9M | -$21.8M | -$21.8M |
| Income Tax | - | -$4.0K | $1.8M | $1.3M | - | - | - |
| Net Income | -$65.8M | -$80.9M | -$29.7M | -$203.7M | -$203.7M | -$21.8M | -$21.8M |
| EPS (Basic) | -$1.12 | $0.35 | -$7.74 | -$7.74 | - | - | - |
| EPS (Diluted) | -$1.12 | $0.35 | -$7.74 | -$7.74 | -$2.15 | -$2.16 | -$2.16 |
| Shares Outstanding | 27.0M | 26.8M | 26.6M | 26.4M | 26.2M | 15.1M | 10.7M |
| Operating Margin | -93.0% | -62.8% | -46.9% | -1641.3% | -1641.3% | -138.5% | -138.5% |
| Profit Margin | -80.2% | -53.1% | -17.8% | -1648.0% | -1648.0% | -138.3% | -138.3% |